EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study

Alessandro Rizzo, Fernando Sabino Marques Monteiro, Veronica Mollica, Oronzo Brunetti, Elsa Vitale, Angela Monica Sciacovelli, Andrey Soares, Francesco Massari, Matteo Santoni

Clinical & Experimental Metastasis · 2025

DOI: 10.1007/s10585-024-10327-w ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical & Experimental Metastasis, 2025. Verfasst von Alessandro Rizzo und 8 weiteren Autor:innen. Beteiligte Einrichtung: S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy. rizzo.ale…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Carcinoma, Renal Cell, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune-based combinations have significantly improved the treatment of metastatic renal cell carcinoma (mRCC); however, immunotherapy has reported varying degrees of efficacy across different metastatic sites, with liver and bone metastases traditionally considered more challenging to treat. In MOUSEION-08 study, we aimed to investigate the association between lung, liver, and bone metastases and clinical outcomes such as Overall Survival (OS) and Progression- Free Survival (PFS) in mRCC patients receiving immune-based combinations. The present systematic review and study-level meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). PFS and OS were measured as Hazard Ratios (HRs) and 95% confidence intervals (CIs). The protocol was registered with PROSPERO, Registration number: CRD42024581488. Our search resulted in the identification of 2364 potentially relevant reports, which were subsequently restricted to three. The pooled HRs for OS and PFS in patients with lung metastases receiving immune-based combinations versus sunitinib were 0.61 (95% CI, 0.51-0.72) and 0.47 (95% CI, 0.38-0.59), respectively. In patients with liver metastases, the pooled HRs for OS and PFS were 0.56 (95% CI, 0.42-0.75) and 0.48 (95% CI, 0.34-0.67), while the pooled HRs for OS and PFS in patients with bone metastases were 0.64 (95% CI, 0.49-0.84) and 0.36 (95% CI, 0.27-0.49), respectively. According to our findings, the analyses reported similar HRs for OS and PFS, something that further underlines the role of immune-based combinations in this setting, regardless of metastatic sites, such as lung, liver, and bone metastases. Ongoing research and clinical trials are destined to refine and improve immunotherapeutic strategies for mRCC, aiming to enhance efficacy across all metastatic sites and to define predictive biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsCarcinoma, Renal CellImmunotherapyKidney NeoplasmsLiver NeoplasmsLung NeoplasmsHumansProgression-Free SurvivalRandomized Controlled Trials as TopicSunitinib

Stichwörter der Autor:innen

Bone metastasesImmune-based combinationsImmunotherapyLiver metastasesLung metastasesRenal cell carcinoma

Substanzen

Sunitinib

Autor:innen und Institutionen

  • S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy. rizzo.alessandro179@gmail.com.
  • Latin American Cooperative Oncology Group - LACOG, Porto Alegre, RS, Brazil.
  • Oncology and Hematology Department, Hospital Sírio-Libanês, Brasilia, DF, Brazil.
  • Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy.
  • Scientific Directorate, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.

Zitieren

APA

Rizzo, A., Monteiro, F. S. M., Mollica, V., Brunetti, O., Vitale, E., Sciacovelli, A. M., Soares, A., Massari, F., & Santoni, M. (2025). Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study. Clinical & Experimental Metastasis. https://doi.org/10.1007/s10585-024-10327-w

Vancouver

Rizzo A, Monteiro FSM, Mollica V, Brunetti O, Vitale E, Sciacovelli AM, et al. Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study. Clinical & Experimental Metastasis. 2025. doi:10.1007/s10585-024-10327-w

BibTeX
@article{Rizzo2025,
  author = {Rizzo, Alessandro and Monteiro, Fernando Sabino Marques and Mollica, Veronica and Brunetti, Oronzo and Vitale, Elsa and Sciacovelli, Angela Monica and Soares, Andrey and Massari, Francesco and Santoni, Matteo},
  title = {Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study},
  journal = {Clinical & Experimental Metastasis},
  year = {2025},
  doi = {10.1007/s10585-024-10327-w}
}
Kostenlos starten →